Radiopharmaceuticals and Nanotechnology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 25 August 2024 | Viewed by 165
Special Issue Editors
Interests: radiobiology; nanomedicine; radiosensitizer; DNA damage; high-LET radiation
Special Issues, Collections and Topics in MDPI journals
Interests: radiobiology; nanomedicine; radio-induced immune response; external radiotherapy; immunotherapy
Special Issue Information
Dear Colleagues,
Over the past decades, the development of nanomedicine has offered the possibility to exploit nanoscale materials for a wide range of applications, improving the diagnosis and treatment of serious diseases. Numerous proofs-of-concept and developments were recently published, opening up possibilities for targeted and personalized therapy, changing the paradigm of cancer treatment from the conventional local approach to a more systemic one. These promising results also raised some questions about the challenges of rapidly transitioning these technologies to the clinic and highlighted the need for multi-disciplinary teams that join forces.
In this special issue of Pharmaceuticals, we aim to provide exciting insights into state-of-the-art research as well as future developments in the field of nanotechnologies for radiation-based diagnosis and treatment. We invite transdisciplinary teams to submit papers (full research papers, short communications and review) covering a range of topics in the field including, but not limited to:
- The design and synthesis of novel nanomaterials/tracers;
- The use of nanotechnology for multi-modal applications including targeted drug delivery, imaging or radiation therapy;
- Characterization and modelling of the pharmacokinetics/pharmacodynamics of radiopharmaceuticals and nano-objects;
- New in vivo (pre)-clinical validations of nanomaterials and radiopharmaceuticals for the treatment of cancer and other diseases;
- Nanotechnology-enhanced dosimetry of radiotherapy and radiopharmaceutical therapy.
Dr. Sébastien Penninckx
Dr. Céline Mirjolet
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceutics
- nanoparticle
- radiation (external beam radiotherapy, nuclear medicine, brachytherapy, PET, SPECT, …)
- theranostic
- nanomedicine
